UTHR,DOC Stock Price and Quote

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: AMGN PFE LLY MRK REGN JNJ BMY VRTX GILD BIIB

| Held by: IJH VTI VB VBR VXF XMHQ MDY IBB IJK SPMD

Index	-	P/E	17.93	EPS (ttm)	26.39	Insider Own	3.52%	Shs Outstand	42.90M	Perf Week	-0.40%
Market Cap	20.37B	Forward P/E	15.49	EPS next Y	30.55	Insider Trans	-41.86%	Shs Float	41.54M	Perf Month	-3.61%
Enterprise Value	17.60B	PEG	1.49	EPS next Q	7.16	Inst Own	95.61%	Short Float	4.30%	Perf Quarter	4.21%
Income	1.27B	P/S	6.51	EPS this Y	11.67%	Inst Trans	-3.94%	Short Ratio	4.35	Perf Half Y	56.92%
Sales	3.13B	P/B	3.08	EPS next Y	11.04%	ROA	17.57%	Short Interest	1.78M	Perf YTD	-2.90%
Book/sh	153.61	P/C	7.36	EPS next 5Y	10.37%	ROE	20.04%	52W High	519.99 -9.01%	Perf Year	33.74%
Cash/sh	64.28	P/FCF	18.16	EPS past 3/5Y	34.80% -	ROIC	19.30%	52W Low	266.98 77.21%	Perf 3Y	82.33%
Dividend Est.	-	EV/EBITDA	11.01	Sales past 3/5Y	19.52% 14.71%	Gross Margin	88.59%	Volatility	2.51% 2.15%	Perf 5Y	178.62%
Dividend TTM	-	EV/Sales	5.63	EPS Y/Y TTM	17.16%	Oper. Margin	48.46%	ATR (14)	11.18	Perf 10Y	276.66%
Dividend Ex-Date	-	Quick Ratio	6.07	Sales Y/Y TTM	13.50%	Profit Margin	40.65%	RSI (14)	45.77	Recom	1.60
Dividend Gr. 3/5Y	- -	Current Ratio	6.40	EPS Q/Q	12.12%	SMA20	-0.17%	Beta	0.86	Target Price	540.27
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	6.76%	SMA50	-2.73%	Rel Volume	0.78	Prev Close	485.36
Employees	1305	LT Debt/Eq	0.00	Earnings	Oct 29 BMO	SMA200	21.86%	Avg Volume	410.27K	Price	473.12
IPO	Jun 17, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.14% -1.64%	Trades		Volume	320,354	Change	-2.52%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Underweight	$414
Sep-26-25	Initiated	RBC Capital Mkts	Outperform	$569
Jun-02-25	Initiated	Cantor Fitzgerald	Overweight	$405
Apr-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-21-25	Upgrade	BofA Securities	Underperform → Neutral	$314
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$310 → $321
Feb-12-24	Upgrade	Goldman	Sell → Neutral	$213 → $215
Feb-05-24	Initiated	Leerink Partners	Outperform	$330
Dec-08-23	Initiated	Wells Fargo	Overweight	$309
Dec-06-22	Initiated	UBS	Buy	$320
Dec-05-22	Initiated	Goldman	Sell	$230
Oct-11-22	Initiated	Morgan Stanley	Overweight	$288
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform	$263
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy	$205
Apr-26-21	Resumed	Credit Suisse	Outperform	$196
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy	$125 → $195
Sep-14-20	Resumed	JP Morgan	Overweight	$142
Jun-25-20	Reiterated	H.C. Wainwright	Neutral	$85 → $125

Show Previous Ratings

Feb-06-26 11:04AM	Merck's Subdued 2026 Outlook: What it Means After Q4 Results? (Zacks)
Jan-29-26 10:32PM	A Look Back at Therapeutics Stocks' Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack (StockStory)
Jan-28-26 10:15AM	Merck's Non-Oncology Drugs Q4 Performance: What to Expect (Zacks)
Jan-27-26 10:33PM	Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR) (StockStory)
Jan-26-26 08:55AM	United Therapeutics Reports Early Success For External Liver Support In Acute Failure (Benzinga)
07:00AM	Loading…
07:00AM	United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP in Patients with Acute Liver Failure (Business Wire)
Jan-22-26 07:00AM	United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors (Business Wire)
Jan-19-26 05:17PM	United Therapeutics Corporation (UTHR): A Bull Case Theory (Insider Monkey)
Jan-16-26 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
Jan-15-26 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
Jan-13-26 10:39AM	6 stocks and ETFs that these unsung market heroes see outperforming in 2026 (MarketWatch)
Jan-12-26 03:57PM	6 stocks and ETFs that these unsung market heroes see outperforming in 2026 (MarketWatch)
08:55AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
Jan-08-26 11:40AM	UTHR or MDGL: Which Is the Better Value Stock Right Now? (Zacks)
Jan-07-26 11:40AM	UTHR vs. ZTS: Which Stock Is the Better Value Option? (Zacks)
07:00AM	Loading…
Jan-05-26 07:00AM	United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
Dec-30-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
Dec-15-25 09:50AM	MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH (Zacks)
Dec-11-25 09:50AM	Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock (Zacks)
Dec-10-25 11:30AM	Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? (Zacks)
09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term (Zacks)
Dec-09-25 12:26PM	This Gold Stock Hits A High, With Miner Poised For Huge Swing To Profit (Investor's Business Daily)
09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
Dec-05-25 11:30AM	Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 11:30AM	Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue? (Zacks)
11:20AM	Can Merck's New Products Aid Growth as Keytruda LOE Test Looms? (Zacks)
Dec-03-25 07:19AM	Flurry of Bullish Inflows Sends United Therapeutics Higher (FX Empire)
Nov-21-25 12:04PM	United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base (Investor's Business Daily)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:45AM	Loading…
Nov-20-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
Nov-19-25 10:52AM	Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study (Zacks)
Nov-12-25 09:50AM	Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-09-25 11:02PM	3 Reasons Investors Love United Therapeutics (UTHR) (StockStory)
Nov-05-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
12:35AM	The 5 Most Interesting Analyst Questions From United Therapeutics's Q3 Earnings Call (StockStory)
Nov-04-25 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
07:00AM	United Therapeutics Corporation to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-25 07:00AM	United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease (Business Wire)
Oct-30-25 03:48PM	United Therapeutics Corp (UTHR) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
11:40AM	MKKGY vs. UTHR: Which Stock Is the Better Value Option? (Zacks)
01:38AM	UTHR Q3 Deep Dive: Clinical Pipeline Advances and High-Dose Product Launches Drive Outlook (StockStory)
Oct-29-25 04:14PM	United Therapeutics Rockets 10% On Growing Enthusiasm For Its Top Drug (Investor's Business Daily) +9.63%
01:11PM	Why Is United Therapeutics (UTHR) Stock Soaring Today (StockStory)
11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
09:55AM	The Mixed Results For United Therapeutics' Bread-And-Butter Drug (Investor's Business Daily)
09:30AM	Compared to Estimates, United Therapeutics (UTHR) Q3 Earnings: A Look at Key Metrics (Zacks)
08:51AM	United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short (Investor's Business Daily)
07:40AM	United Therapeutics (UTHR) Beats Q3 Earnings Estimates (Zacks)
06:48AM	United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings (StockStory)
06:43AM	United Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results (Business Wire)
Oct-27-25 11:17PM	United Therapeutics (UTHR) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-24-25 10:05AM	Merck's Non-Oncology Drugs Q3 Performance: What to Expect (Zacks)
Oct-23-25 10:00AM	Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-22-25 10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Oct-16-25 03:51PM	Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case (Insider Monkey)
Oct-15-25 07:00AM	United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025 (Business Wire)
Oct-13-25 07:00AM	United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting (Business Wire)
Oct-01-25 10:40AM	Is IPF the Next Big Market Opportunity for United Therapeutics? (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Sep-30-25 04:38PM	Top Stock Reports for NextEra Energy, U.S. Bancorp and Air Products & Chemicals (Zacks)
Sep-26-25 09:46AM	CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls (The Fly)
Sep-19-25 11:53AM	Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE? (Zacks)
07:00AM	United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso in Idiopathic Pulmonary Fibrosis (Business Wire)
12:46AM	1 Momentum Stock to Target This Week and 2 We Brush Off (StockStory)
12:03AM	3 Big Reasons to Love United Therapeutics (UTHR) (StockStory)
Sep-16-25 07:00AM	United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum (Business Wire)
Sep-12-25 07:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress (Business Wire)
Sep-11-25 11:30AM	Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-10-25 02:46PM	United Therapeutics Price Strength Rating Jumps; Stock Soared 33% Last Week (Investor's Business Daily)
Sep-03-25 01:48PM	UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals (Zacks)
09:00AM	Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint (TipRanks)
08:52AM	Pharma, Opendoor, Tesla: Trending Stocks (Yahoo Finance Video)
06:30AM	Lung Disease Breakthrough Boosts United Therapeutics and its Rivals (The Daily Upside)
Sep-02-25 04:09PM	Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It (Investor's Business Daily) +32.83%
09:34AM	Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
07:00AM	United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis (Business Wire)
Aug-29-25 11:30AM	Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report? (Zacks)
07:00AM	United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-13-25 12:05AM	5 Insightful Analyst Questions From United Therapeutics's Q2 Earnings Call (StockStory)
Aug-12-25 11:40PM	UTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive Uncertainty (StockStory)
04:06PM	Liquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent Battle (Investor's Business Daily)
10:00AM	Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It (Investor's Business Daily)
Aug-11-25 04:15PM	3D Systems Reports Second Quarter 2025 Financial Results (GlobeNewswire)
11:32AM	Merck's Narrowed 2025 Sales View: What it Means After Q2 Results? (Zacks)
Aug-01-25 07:00AM	United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program (Business Wire) +7.13%
Jul-31-25 10:15AM	UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y (Zacks)
Jul-30-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks) -5.25%
09:30AM	Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics (Zacks)
07:35AM	United Therapeutics (UTHR) Misses Q2 Earnings Estimates (Zacks)
06:46AM	United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates (StockStory)
06:36AM	United Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results (Business Wire)
Jul-28-25 11:13PM	What To Expect From United Therapeutics's (UTHR) Q2 Earnings (StockStory)
10:00AM	Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline (Zacks)
02:07AM	Leerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT (Insider Monkey)
Jul-25-25 10:42PM	United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial (Insider Monkey)
Jul-24-25 09:50AM	United Therapeutics (UTHR) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 05 '26	Option Exercise	146.03	8,300	1,212,049	45,081	Feb 05 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 05 '26	Sale	483.25	8,300	4,010,940	36,781	Feb 05 04:31 PM
PAUL MAHON	Officer	Feb 05 '26	Proposed Sale	483.25	8,300	4,010,939		Feb 05 04:03 PM
MALCOLM JAN	Director	Feb 03 '26	Sale	474.23	50	23,712	270	Feb 03 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 02 '26	Option Exercise	127.65	22,500	2,872,226	14,625	Feb 03 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 02 '26	Sale	470.95	22,500	10,596,429	0	Feb 03 04:31 PM
JAN MALCOLM	Director	Feb 03 '26	Proposed Sale	474.23	50	23,712		Feb 03 04:03 PM
Michael Benkowitz	Officer	Feb 02 '26	Proposed Sale	469.49	90,000	42,254,100		Feb 02 04:29 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 26 '26	Option Exercise	127.65	22,500	2,872,226	14,625	Jan 28 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 20 '26	Option Exercise	146.03	7,875	1,149,986	7,875	Jan 28 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 26 '26	Sale	471.91	22,500	10,617,932	0	Jan 28 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 20 '26	Sale	464.66	7,875	3,659,182	0	Jan 28 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 20 '26	Sale	464.66	14,625	6,795,627	0	Jan 28 04:30 PM
MALCOLM JAN	Director	Jan 16 '26	Sale	460.98	50	23,049	320	Jan 20 04:30 PM
JAN MALCOLM	Director	Jan 20 '26	Proposed Sale	460.98	50	23,049		Jan 20 04:02 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 15 '26	Option Exercise	146.03	8,300	1,212,049	45,081	Jan 15 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 15 '26	Sale	469.89	8,300	3,900,122	36,781	Jan 15 04:32 PM
PAUL MAHON	Officer	Jan 15 '26	Proposed Sale	469.89	8,300	3,900,122		Jan 15 04:06 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 12 '26	Option Exercise	127.65	22,500	2,872,226	14,625	Jan 13 05:10 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 12 '26	Sale	479.51	22,500	10,788,876	0	Jan 13 05:10 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 05 '26	Option Exercise	117.76	14,625	1,722,240	14,625	Jan 07 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 05 '26	Sale	487.38	14,625	7,127,877	0	Jan 07 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 05 '26	Option Exercise	146.03	7,875	1,149,986	7,875	Jan 07 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 05 '26	Sale	487.38	7,875	3,838,085	0	Jan 07 04:30 PM
CAUSEY CHRISTOPHER	Director	Jan 06 '26	Option Exercise	119.76	1,000	119,760	5,190	Jan 06 04:31 PM
CAUSEY CHRISTOPHER	Director	Jan 06 '26	Sale	510.00	1,000	510,000	4,190	Jan 06 04:31 PM
MALCOLM JAN	Director	Jan 05 '26	Sale	495.01	50	24,750	370	Jan 06 04:31 PM
CHRISTOPHER CAUSEY	Director	Jan 06 '26	Proposed Sale	510.00	1,000	510,000		Jan 06 04:07 PM
JAN MALCOLM	Director	Jan 06 '26	Proposed Sale	495.01	50	24,750		Jan 06 04:06 PM
CAUSEY CHRISTOPHER	Director	Jan 02 '26	Option Exercise	119.76	1,000	119,760	5,190	Jan 05 04:59 PM
CAUSEY CHRISTOPHER	Director	Jan 02 '26	Sale	500.01	1,000	500,015	4,190	Jan 05 04:59 PM
Michael Benkowitz	Officer	Jan 05 '26	Proposed Sale	496.72	90,000	44,704,800		Jan 05 04:39 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 02 '26	Option Exercise	146.03	8,300	1,212,049	45,081	Jan 02 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 02 '26	Sale	485.43	8,300	4,029,076	36,781	Jan 02 04:30 PM
CHRISTOPHER CAUSEY	Director	Jan 02 '26	Proposed Sale	500.01	1,000	500,015		Jan 02 04:22 PM
PAUL MAHON	Officer	Jan 02 '26	Proposed Sale	485.43	8,300	4,029,076		Jan 02 04:12 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 29 '25	Option Exercise	146.03	7,875	1,149,986	7,875	Dec 30 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 29 '25	Sale	502.79	22,500	11,312,710	0	Dec 30 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 24 '25	Option Exercise	146.03	11,000	1,606,330	47,781	Dec 29 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 24 '25	Sale	513.18	11,000	5,644,954	36,781	Dec 29 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 22 '25	Option Exercise	146.03	7,875	1,149,986	7,875	Dec 29 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 22 '25	Sale	514.35	22,500	11,572,963	0	Dec 29 04:30 PM
PAUL MAHON	Officer	Dec 24 '25	Proposed Sale	513.18	11,000	5,644,954		Dec 29 09:37 AM
MALCOLM JAN	Director	Dec 23 '25	Sale	512.12	50	25,606	420	Dec 23 04:33 PM
SULLIVAN LOUIS W	Director	Dec 22 '25	Option Exercise	204.93	5,950	1,219,339	5,950	Dec 23 04:33 PM
SULLIVAN LOUIS W	Director	Dec 22 '25	Sale	512.13	5,950	3,047,201	0	Dec 23 04:33 PM
LOUIS WADE SULLIVAN REVOCABLE	Affiliate	Dec 22 '25	Proposed Sale	512.13	5,950	3,047,200		Dec 22 05:13 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 19 '25	Proposed Sale	507.07	2,000	1,014,143		Dec 19 05:39 PM
Thompson Tommy G	Director	Dec 18 '25	Option Exercise	101.80	910	92,638	9,390	Dec 19 04:31 PM
Thompson Tommy G	Director	Dec 18 '25	Sale	500.59	910	455,533	8,480	Dec 19 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 17 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 18 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 19 '25	Option Exercise	120.26	2,000	240,520	2,130	Dec 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 18 '25	Sale	508.87	4,000	2,035,488	130	Dec 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 17 '25	Sale	501.04	4,000	2,004,147	130	Dec 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 19 '25	Sale	507.07	2,000	1,014,143	130	Dec 19 04:30 PM
TOMMY THOMPSON	Director	Dec 18 '25	Proposed Sale	500.59	910	455,533		Dec 18 04:09 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 18 '25	Proposed Sale	508.87	4,000	2,035,488		Dec 18 04:00 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 17 '25	Proposed Sale	501.04	4,000	2,004,152		Dec 17 04:52 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 15 '25	Option Exercise	146.03	3,517	513,588	11,659	Dec 16 05:09 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 15 '25	Sale	495.36	3,517	1,742,193	8,142	Dec 16 05:09 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 15 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 16 05:08 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 16 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 16 05:08 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 15 '25	Sale	494.72	4,000	1,978,869	130	Dec 16 05:08 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 16 '25	Sale	493.45	4,000	1,973,820	130	Dec 16 05:08 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 15 '25	Option Exercise	244.05	22,500	5,491,040	14,625	Dec 16 04:33 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 15 '25	Sale	496.30	22,500	11,166,722	0	Dec 16 04:33 PM
PATUSKY CHRISTOPHER	Director	Dec 15 '25	Option Exercise	101.80	1,000	101,800	2,490	Dec 16 04:30 PM
PATUSKY CHRISTOPHER	Director	Dec 15 '25	Sale	495.95	1,000	495,954	1,490	Dec 16 04:30 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 16 '25	Proposed Sale	493.45	4,000	1,973,820		Dec 16 04:01 PM
CHRISTOPHER PATUSKY	Director	Dec 15 '25	Proposed Sale	495.95	1,000	495,954		Dec 15 05:45 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 15 '25	Proposed Sale	494.72	4,000	1,978,869		Dec 15 04:57 PM
MALCOLM JAN	Director	Dec 11 '25	Sale	482.98	50	24,149	470	Dec 12 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 11 '25	Option Exercise	146.03	11,000	1,606,330	47,781	Dec 12 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 11 '25	Sale	484.67	11,000	5,331,316	36,781	Dec 12 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 11 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 12 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 12 '25	Sale	490.70	4,000	1,962,783	130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 11 '25	Sale	483.97	4,000	1,935,879	130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 12 '25	Proposed Sale	490.70	4,000	1,962,783		Dec 12 04:04 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 11 '25	Proposed Sale	483.97	4,000	1,935,879		Dec 11 04:10 PM
PAUL MAHON	Officer	Dec 11 '25	Proposed Sale	484.67	11,000	5,331,316		Dec 11 04:06 PM
Mesa Nilda	Director	Dec 09 '25	Sale	481.63	187	90,065	5,286	Dec 10 04:54 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 09 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 10 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 10 '25	Sale	480.05	4,000	1,920,191	130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 09 '25	Sale	478.30	4,000	1,913,184	130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 10 '25	Proposed Sale	480.05	4,000	1,920,190		Dec 10 03:52 PM
NILDA MESA	Director	Dec 09 '25	Proposed Sale	481.63	187	90,065		Dec 09 06:01 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 08 '25	Option Exercise	146.03	21,000	3,066,630	29,142	Dec 09 04:54 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 08 '25	Sale	478.60	21,000	10,050,597	8,142	Dec 09 04:54 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 08 '25	Option Exercise	244.05	22,500	5,491,040	14,625	Dec 09 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 08 '25	Sale	478.58	22,500	10,768,000	0	Dec 09 04:31 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 09 '25	Proposed Sale	478.30	4,000	1,913,184		Dec 09 03:47 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 08 '25	Proposed Sale	484.23	4,000	1,936,936		Dec 08 06:25 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 05 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 08 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 08 '25	Sale	484.23	4,000	1,936,936	130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 05 '25	Sale	483.28	4,000	1,933,120	130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 03 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 05 04:54 PM

DOC Healthpeak Properties Inc daily Stock Chart

Peers: WELL VTR HCP OHI MPT HR NHI LTC SBRA GMRE

| Held by: VNQ VTI VOO VB RSP VBR IVV SPY XLRE SPHD

Index	S&P 500	P/E	166.57	EPS (ttm)	0.10	Insider Own	0.33%	Shs Outstand	695.04M	Perf Week	-0.47%
Market Cap	11.99B	Forward P/E	57.42	EPS next Y	0.29	Insider Trans	0.00%	Shs Float	692.74M	Perf Month	-1.17%
Enterprise Value	22.57B	PEG	1.28	EPS next Q	0.07	Inst Own	96.97%	Short Float	3.70%	Perf Quarter	-4.10%
Income	70.51M	P/S	4.25	EPS this Y	165.47%	Inst Trans	1.06%	Short Ratio	3.08	Perf Half Y	-0.71%
Sales	2.82B	P/B	1.56	EPS next Y	10.47%	ROA	0.35%	Short Interest	25.61M	Perf YTD	4.73%
Book/sh	10.79	P/C	22.30	EPS next 5Y	45.02%	ROE	0.89%	52W High	21.28 -20.86%	Perf Year	-16.30%
Cash/sh	0.76	P/FCF	10.46	EPS past 3/5Y	-52.08% -	ROIC	0.42%	52W Low	15.71 7.19%	Perf 3Y	-38.91%
Dividend Est.	1.25 (7.40%)	EV/EBITDA	14.07	Sales past 3/5Y	11.05% 11.40%	Gross Margin	22.48%	Volatility	2.63% 2.55%	Perf 5Y	-42.48%
Dividend TTM	1.32 (7.87%)	EV/Sales	8.00	EPS Y/Y TTM	-70.88%	Oper. Margin	19.31%	ATR (14)	0.43	Perf 10Y	-47.09%
Dividend Ex-Date	Feb 13, 2026	Quick Ratio	1.66	Sales Y/Y TTM	4.52%	Profit Margin	2.50%	RSI (14)	45.95	Recom	2.06
Dividend Gr. 3/5Y	0.55% -3.79%	Current Ratio	1.66	EPS Q/Q	2500.00%	SMA20	-2.52%	Beta	1.11	Target Price	19.36
Payout	1204.37%	Debt/Eq	1.38	Sales Q/Q	3.07%	SMA50	-0.56%	Rel Volume	0.68	Prev Close	16.85
Employees	411	LT Debt/Eq	1.24	Earnings	Feb 02 AMC	SMA200	-4.38%	Avg Volume	8.30M	Price	16.84
IPO	Jul 19, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	128.57% 1.90%	Trades		Volume	5,709,302	Change	-0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-05-26	Downgrade	Argus	Buy → Hold
Jan-09-26	Initiated	Goldman	Neutral	$17
Dec-16-25	Downgrade	Jefferies	Buy → Hold	$17
Oct-01-25	Initiated	Cantor Fitzgerald	Neutral	$20
Sep-15-25	Upgrade	Raymond James	Mkt Perform → Outperform	$20
Aug-20-25	Downgrade	Deutsche Bank	Buy → Hold	$18
Jul-29-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$19
Jan-15-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$25
Oct-21-24	Upgrade	Deutsche Bank	Hold → Buy	$20 → $28
May-03-24	Upgrade	Wedbush	Neutral → Outperform
Apr-26-24	Upgrade	Exane BNP Paribas	Neutral → Outperform	$19 → $21
Apr-22-24	Resumed	Mizuho	Buy	$22
Apr-01-24	Upgrade	BofA Securities	Underperform → Buy	$18 → $25
Mar-25-24	Resumed	Wells Fargo	Equal Weight	$19
Mar-08-24	Resumed	RBC Capital Mkts	Outperform	$21
Jan-05-24	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
May-26-23	Initiated	JMP Securities	Mkt Outperform	$15.50
Apr-20-23	Initiated	Wells Fargo	Underweight	$14
Dec-14-22	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$17
Oct-28-22	Initiated	JP Morgan	Neutral	$17

Show Previous Ratings

Feb-06-26 11:28AM	Ventas Q4 FFO Meet, Revenues Beat Estimates, Same-Store Cash NOI Rises (Zacks)
Feb-04-26 12:48PM	2 REITs That Look Attractive in a Stable Rate Environment (MarketBeat)
Feb-03-26 10:08PM	Healthpeak Properties Q4 Earnings Call Highlights (MarketBeat)
04:48PM	Analyst Report: Healthpeak Properties, Inc. (Morningstar Research)
04:21PM	Goldman Sachs Highlights Improving Occupancy and Cash Flow Visibility at Healthpeak Properties Inc. (DOC) (Insider Monkey)
04:02PM	Loading…
04:02PM	Healthpeak Properties Inc (DOC) Q4 2025 Earnings Call Highlights: Strategic Moves and ... (GuruFocus.com)
08:34AM	Healthpeak Q4 FFO Beats Estimates, Same-Store NOI Rises Y/Y (Zacks)
04:58AM	What Are Wall Street Analysts' Target Price for Healthpeak Properties Stock? (Barchart)
Feb-02-26 05:35PM	Healthpeak (DOC) Beats Q4 FFO and Revenue Estimates (Zacks)
04:42PM	Healthpeak: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Healthpeak Properties Provides Strategic Initiatives Update and Reports Fourth Quarter 2025 Results (Business Wire)
Jan-29-26 05:25PM	Analyst Report: Healthpeak Properties, Inc. (Morningstar Research)
11:12AM	What's in the Cards for Healthpeak Properties This Earnings Season? (Zacks)
09:18AM	Boomers and Gen-X Are Grabbing 5 Passive Income High-Yield Giants Before 2026 Rate Cuts (24/7 Wall St.)
09:00AM	SL Green's Q4 FFO & Revenues Beat Estimates, Rental Rates Improve (Zacks)
08:25AM	Loading…
Jan-28-26 08:25AM	Boston Properties' Q4 Revenues and FFO Miss Estimates (Zacks)
Jan-27-26 11:12AM	Alexandria's Q4 AFFO & Revenues Beat Estimates, Occupancy Decline Y/Y (Zacks)
Jan-22-26 09:48AM	Healthpeak Properties Stock Up 13.5% in a Month: Will the Trend Last? (Zacks)
Jan-21-26 04:15PM	Healthpeak Advances AI-Enabled Operating Platform, Naming Omkar Joshi Head of Enterprise Innovation (Business Wire)
10:56AM	Prologis Q4 FFO Meets Estimates, Rental Revenues Rise Y/Y (Zacks)
09:35AM	Should You Forget Realty Income and Buy Healthpeak Properties Instead? (Motley Fool)
Jan-20-26 11:53AM	Monthly Income: A Portfolio of 2 ETFs and 2 Stocks (24/7 Wall St.)
Jan-15-26 04:15PM	Healthpeak Properties Announces Tax Treatment of 2025 Distributions (Business Wire)
Jan-14-26 10:24AM	Healthpeak Announces Transaction Activity Amounting $925 Million (Zacks)
Jan-12-26 06:59AM	Healthpeak Properties Announces $925 Million of Transaction Activity (Business Wire)
Jan-09-26 04:15PM	Healthpeak Properties Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details (Business Wire)
Jan-08-26 08:46AM	Healthpeak Monetizes Senior Housing Assets Through Janus Living IPO (Zacks)
Jan-07-26 07:01AM	Healthpeak Properties Announces the Formation of a Pure-Play, RIDEA-Structured Publicly Traded Senior Housing REIT (Business Wire)
07:00AM	Healthpeak Properties Announces Confidential Submission of Draft Registration Statement by Janus Living, Inc. (Business Wire)
Jan-05-26 04:15PM	Healthpeak Properties Declares Monthly Common Stock Cash Dividends for the First Quarter of 2026 (Business Wire)
05:42AM	Loading…
05:42AM	What You Need To Know Ahead of Healthpeak Properties Earnings Release (Barchart)
Dec-31-25 09:40AM	Here's Why Healthpeak (DOC) is a Strong Value Stock (Zacks)
Dec-26-25 08:55AM	How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings (Zacks)
Dec-20-25 05:35AM	6 Ultra-High-Yield Dividend Stocks for Safe Income in 2026 and Beyond (Motley Fool)
Dec-18-25 09:41AM	3 New Year's Resolution Stocks That Could Turn Around in 2026 (MarketBeat)
03:04AM	Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500? (Motley Fool)
Dec-17-25 09:41AM	More Rate Cuts Are Coming in 2026: Grab These Safe 7% and 8% Dividend Stocks Now (24/7 Wall St.)
Dec-16-25 09:09AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More (24/7 Wall St.)
Dec-15-25 05:09AM	Is Healthpeak Properties Stock Underperforming the Dow? (Barchart)
Dec-11-25 09:40AM	Why Healthpeak (DOC) is a Top Value Stock for the Long-Term (Zacks)
Dec-10-25 11:47AM	This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500) (24/7 Wall St.)
Dec-08-25 06:00AM	Healthpeak Properties Publishes Updated Investor Presentation (Business Wire)
Dec-07-25 08:25PM	Got $2,000 to Invest in December? These Dividend Stocks Could Turn It into a Monthly Stream of Passive Income in 2026. (Motley Fool)
Dec-04-25 05:03PM	Wall Street Sees a 60% Upside to Healthpeak Properties (DOC) (Insider Monkey)
Nov-27-25 11:30AM	W.P. Carey (WPC) Up 1.7% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-26-25 11:30AM	Why Is Alexandria Real Estate Equities (ARE) Down 16.4% Since Last Earnings Report? (Zacks)
Nov-25-25 11:48AM	3 Best Monthly Paying Dividend Stocks in the S&P 500 (24/7 Wall St.)
Nov-20-25 09:57AM	Analyst Report: Healthpeak Properties, Inc. (Morningstar Research)
Nov-11-25 06:36PM	Analyst Report: Healthpeak Properties, Inc. (Morningstar Research)
Nov-05-25 01:15PM	Healthpeak Properties Stock: Is Wall Street Bullish or Bearish? (Barchart)
Nov-04-25 01:38PM	3 High-Yield Monthly Dividend Stocks That Pay You Like Clockwork (24/7 Wall St.)
Nov-03-25 07:03AM	3 Safe and Steady Stocks for Any Market (MarketBeat)
Oct-30-25 01:27PM	Ventas Q3 FFO and Revenues Beat Estimates, Same-Store Cash NOI Rises (Zacks)
01:07PM	Equinix Q3 AFFO Beats Estimates, Recurring Revenues Rise Y/Y (Zacks)
Oct-28-25 12:22PM	Welltower's Q3 FFO & Revenues Beat Estimates, Same Store NOI Rises (Zacks) -5.40%
Oct-24-25 05:02PM	Healthpeak Properties Inc (DOC) Q3 2025 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
01:34PM	Healthpeak Q3 FFO Beats Estimates, Same-Store NOI Rises Y/Y (Zacks)
Oct-23-25 06:00PM	Healthpeak (DOC) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:25PM	Healthpeak (DOC) Beats Q3 FFO and Revenue Estimates (Zacks)
04:21PM	Healthpeak: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Healthpeak Properties Provides Strategic Initiatives Update and Reports Third Quarter 2025 Results (Business Wire)
Oct-21-25 11:12AM	What's in the Cards for Healthpeak Properties This Earnings Season? (Zacks)
09:15AM	Wall Street's Insights Into Key Metrics Ahead of Healthpeak (DOC) Q3 Earnings (Zacks)
Oct-16-25 03:07PM	3 Ultra-High-Yield Dividend Stocks With 7.2% Average Yields to Buy in October (Motley Fool)
Oct-15-25 09:10AM	Prologis (PLD) Tops Q3 FFO Estimates (Zacks)
Oct-07-25 02:16AM	What to Expect From Healthpeak Properties Next Quarterly Earnings Report (Barchart)
Oct-06-25 04:15PM	Healthpeak Properties Declares Monthly Common Stock Cash Dividends for the Fourth Quarter of 2025 (Business Wire)
04:51AM	2 Top Dividend Stocks to Buy With Less Than $50 (Motley Fool)
Oct-05-25 08:17AM	Investing $50,000 Into These Top Real Estate Dividend Stocks Could Produce Nearly $250 of Passive Income Each Month (Motley Fool)
Oct-03-25 06:21AM	Is AGNC Investment a Better Dividend Stock Than Healthpeak Properties? (Motley Fool)
Oct-01-25 01:00PM	Dividend Dependability: How Healthpeak Properties (DOC) Supports Long-Term Income Strategies (Insider Monkey)
Sep-28-25 06:33PM	2 No-Brainer Dividend Stocks With Yields Above 5% You Can Buy Now and Hold at Least a Decade (Motley Fool)
Sep-27-25 03:06AM	Investing $2,500 in This Basket of Dividend Stocks Should Give You Nearly $200 in Yearly Income (Motley Fool)
Sep-25-25 04:15PM	Healthpeak Properties Announces Third Quarter 2025 Earnings Release Date and Conference Call Details (Business Wire)
Sep-23-25 03:53AM	Is Healthpeak Properties Stock Underperforming the Nasdaq? (Barchart)
Sep-21-25 04:24AM	Street Calls of the Week (Investing.com)
Sep-15-25 09:40AM	Broadcom initiated, Beyond Meat downgraded: Wall Street's top analyst calls (The Fly)
08:56AM	Raymond James upgrades Healthpeak, downgrades Healthcare Realty to Underperform (Investing.com)
Sep-11-25 04:59AM	2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades (Motley Fool)
Sep-04-25 04:15PM	Healthpeak Properties Publishes Its 14th Annual Corporate Impact Report (Business Wire)
Sep-02-25 03:21AM	3 High-Yield Dividend Stocks You Can Buy in September and Hold Forever (Motley Fool)
Aug-27-25 06:00AM	Healthpeak Strengthens Life Science Leadership with Addition of Denis Sullivan as Managing Director of Lab Investments & San Diego Market Lead and Promotion of Mike Dorris as Head of West Coast Development & Construction (Business Wire)
Aug-23-25 03:11AM	Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 5 Ultra-High-Yield Stocks. (Motley Fool)
Aug-20-25 08:13AM	2 Dirt-Cheap High-Dividend Stocks to Buy Right Now (Motley Fool)
Aug-19-25 02:04PM	Real Estate Is the S&P 500's Best Performer Today (Barrons.com)
Aug-16-25 10:28PM	Here's How You Can Earn $100 In Passive Income By Investing In Healthpeak Properties Stock (Benzinga)
Aug-15-25 10:00AM	Here's Why You Should Retain Welltower Stock in Your Portfolio Now (Zacks)
Aug-14-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-13-25 01:36AM	CEO Share Purchases Contrast Analyst Downgrades for Healthpeak (Insider Monkey)
Aug-07-25 10:21AM	Healthpeak Properties Stock: Analyst Estimates & Ratings (Barchart)
Aug-06-25 04:38AM	Zacks Investment Ideas feature highlights: MSCI, Charter Communications and Healthpeak Properties (Zacks)
Aug-05-25 05:27PM	Healthpeak Prices Offering of $500 Million of 4.750% Senior Unsecured Notes Due 2033 (Business Wire)
11:30AM	These 3 CEOs Just Bought the Dip (Zacks)
Jul-31-25 01:07PM	Ventas Q2 FFO and Revenues Top Estimates, Same-Store Cash NOI Rises (Zacks)
11:41AM	Equinix's Q2 AFFO Beat, Recurring Revenues Rise Y/Y, NFM Rises Q/Q (Zacks)
05:51AM	Want Another $500 in Annual Dividend Income? Invest $6,900 in These 3 High-Yield Stocks. (Motley Fool)
Jul-30-25 04:02PM	UPS Stock Joins 7% Dividend Yielders in S&P 500. Heres Who Else Is in That Club. (Barrons.com)
02:36PM	UPS Stock Joins 7% Yielders in S&P 500. Heres Who Else Is in the Club. (Barrons.com)
Jul-29-25 01:19PM	Welltower's Q2 FFO & Revenues Beat Estimates, Same Store NOI Rises (Zacks)
Jul-26-25 10:36AM	Healthpeak Properties (DOC) Drops 6.7% on Steep Q2 Earnings Dive (Insider Monkey)

Healthpeak Properties, Inc. is a Standard & Poor's 500 company, which engages in acquiring, developing, owning, leasing, and managing healthcare real estate across the United States. It operates through the following segments: Lab, Outpatient Medical, Continuing Care Retirement Community (CCRC), and Other Non-Reportable. The Lab segment refers to lab properties, which contain laboratory and office space. The Outpatient Medical segment includes outpatient medical buildings and hospitals. The CCRC segment deals with retirement communities that include independent living, assisted living, memory care, and skilled nursing units. The Other Non-Reportable segment consists of an unconsolidated joint venture with a sovereign wealth fund that owns 19 senior housing assets and loans receivable. The company was founded in 1985 and is headquartered in Denver, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thomas John T	Director	Aug 06 '25	Buy	17.05	1,450	24,730	810,016	Aug 06 03:09 PM
Brinker Scott M	President and CEO	Aug 04 '25	Buy	16.83	1,490	25,077	211,906	Aug 04 11:16 AM
Brinker Scott M	President and CEO	Jul 31 '25	Buy	17.06	2,930	49,986	210,416	Jul 31 01:59 PM
Brinker Scott M	President and CEO	Jul 28 '25	Buy	17.40	2,873	49,990	207,486	Jul 29 12:02 PM
Scott Peter A	officer in 90 day cool down pe	Jul 01 '25	Proposed Sale	17.88	100,050	1,788,894		Jul 01 06:36 PM
Thompson Tommy G	Director	May 28 '25	Buy	17.27	5,777	99,769	144,290	May 28 01:15 PM
Thompson Tommy G	Director	May 09 '25	Buy	17.36	5,700	98,974	138,513	May 12 12:02 PM
Brinker Scott M	President and CEO	May 09 '25	Buy	17.39	2,750	47,822	204,613	May 12 12:01 PM
Lias-Booker Ava	Director	Apr 29 '25	Buy	17.83	5,000	89,150	35,561	Apr 29 05:06 PM
Thomas John T	Director	Apr 28 '25	Buy	17.84	4,200	74,928	813,566	Apr 28 05:56 PM
Sandstrom Katherine M	Director	Apr 28 '25	Buy	17.65	11,288	199,233	56,268	Apr 28 05:54 PM
Lewis Sara Grootwassink	Director	Apr 28 '25	Buy	17.66	6,000	105,938	9,000	Apr 28 05:52 PM
SHELLEY-KESSLER PAMELA	Director	Apr 28 '25	Buy	17.61	2,838	49,991	3,965	Apr 28 05:51 PM
Brinker Scott M	President and CEO	Apr 28 '25	Buy	17.68	11,337	200,438	201,863	Apr 28 05:49 PM

UTHR

United Therapeutics Corp

DOC

Healthpeak Properties Inc

Upgrade your FINVIZ experience